Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brolucizumab + triamcinolone acetonide
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravitreal, sub-Tenon's
01
Overview
**brolucizumab + triamcinolone acetonide** is a combination therapy used in ophthalmology for the treatment of neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). Brolucizumab is a humanized single-chain antibody fragment that binds to vascular endothelial growth factor A (VEGF-A), inhibiting its activity and thereby reducing abnormal blood vessel growth and leakage in the retina. Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory effects. When administered together—typically as an intravitreal injection of brolucizumab combined with a sub-Tenon’s capsule injection of triamcinolone acetonide—this regimen aims to maximize therapeutic efficacy while minimizing intraocular inflammation associated with brolucizumab monotherapy[2][6][9].
- Brand names
- Beovu (brolucizumab)Triesence (triamcinolone acetonide)
- Other names
- STTA + brolucizumabsub-Tenon's capsule triamcinolone acetonide + intravitreal brolucizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on brolucizumab + triamcinolone acetonide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brolucizumab + triamcinolone acetonide.